---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-046763"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:52:55.086262+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma appoints Dr. Ted Love to board; director Kenneth O'Keefe to retire Dec 1, 2025

## Summary
- Dr. Ted Love appointed as Class I director effective Dec 1, 2025, term expiring at 2027 AGM.
- Love will serve on Audit and Science & Medicine Committees under standard non-employee director compensation.
- Director Kenneth O'Keefe retires from Board effective Dec 1, 2025, with no dispute or disagreement.

## SEC filing metadata
- accession: 0001628280-25-046763
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000162828025046763/0001628280-25-046763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000162828025046763/jazz-20251023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-046763
- JSON: https://secwatch.observer/filing/0001628280-25-046763.json
- Plain text: https://secwatch.observer/filing/0001628280-25-046763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.